IL-2 immunotherapy fails to benefit HIV-infected individuals already taking antiretrovirals

Providing a synthetic form of the immune system protein interleukin-2 (IL-2) to HIV-infected individuals already taking combination antiretroviral therapy boosts their numbers of CD4+ T cells, the key white blood cells destroyed by HIV, but fails to reduce their risk of HIV-associated opportunistic diseases or death compared with combination antiretroviral therapy alone.

If you want to include this story in your blog, copy and paste this formatted text:

<p><a href="http://www.physorg.com/news153514109.html">IL-2 immunotherapy fails to benefit HIV-infected individuals already taking antiretrovirals</a></p> <p>Providing a synthetic form of the immune system protein interleukin-2 (IL-2) to HIV-infected individuals already taking combination antiretroviral therapy boosts their numbers of CD4+ T cells, the key white blood cells destroyed by HIV, but fails to reduce their risk of HIV-associated opportunistic diseases or death compared with combination antiretroviral therapy alone.</p>